Novartis Reports Positive Results From Phase III ASC4FIRST Trial; Meets Both Primary Endpoints
Novartis AG (NVS) reported Friday positive results from the pivotal Phase III ASC4FIRST trial, which met both primary endpoints with clinically meaningful and statistically significant results. Scemblix (asciminib) demonstrated superior MMR rates at week 48 vs. investigator-selected SoC TKIs (imatinib, nilotinib, dasatinib and bosutinib) (67.7% vs. 49.0%) and imatinib alone Scemblix also demonstrated a favorable...